BMJ  2004;329:970-971 (23 October), doi:10.1136/bmj.329.7472.970

Commentary

The PROGRESS trial three years later: time for more action, less distraction

¹ The George Institute for International Health, University of Sydney, PO Box M201, Sydney, NSW 2050, Australia, ² Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand

The first 150 words of the full text of this article appear below.

Since the publication of the results of the PROGRESS trial, there has been much comment in the BMJ and elsewhere.^{1 2} Most of this acknowledges the importance of the findings for the care of patients with cerebrovascular disease. These patients are at high risk of stroke recurrence, and before the trial was completed few interventions had been proved to reduce this risk. Aspirin was known to modestly reduce the risk of recurrence of ischaemic stroke, but no treatment had been shown to reduce the frequently catastrophic recurrence of cerebral haemorrhage. This situation was changed profoundly by the results of PROGRESS, which showed that a simple blood pressure lowering regimen substantially reduced the risks of recurrent stroke,³ disability,⁴ and cardiac events⁵ across a broad range of blood pressure levels in patients with either ischaemic or haemorrhagic cerebrovascular disease.

PROGRESS was conceived during an era in which many stroke specialists were concerned about . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

ASCOT: a tale of two treatment regimens: Odds are that it's hype

Martin G Duerden
BMJ 2005 331: 1022-1023. [Extract] [Full Text]

Perindopril monotherapy and PROGRESS in Europe

Richard Wennberg and Camilla Zimmermann
BMJ 2005 331: 235-236. [Extract] [Full Text]

The PROGRESS trial three years later: time for a balanced report of effectiveness

Richard Wennberg and Camilla Zimmermann
BMJ 2004 329: 968-970. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

• Ong, H. T. (2009). Are Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Especially Useful for Cardiovascular Protection?. J Am Board Fam Med 22: 686-697 [Abstract] [Full text]  
• Duerden, M. G (2005). ASCOT: a tale of two treatment regimens: Odds are that it's hype. BMJ 331: 1022-1023 [Full text]  
• Wennberg, R., Zimmermann, C. (2005). Perindopril monotherapy and PROGRESS in Europe. BMJ 331: 235-236 [Full text]  

Rapid Responses:

Read all Rapid Responses

Understandable Evangelism

Peter Ward
bmj.com, 25 Oct 2004 [Full text]

Perindopril and PROGRESS in Poland

Richard Wennberg, et al.
bmj.com, 10 Mar 2005 [Full text]

Perindopril alone for stroke prevention in Italy: from EBM to ABM

Richard Wennberg, et al.
bmj.com, 31 Mar 2005 [Full text]

Online poll

Find out more>>